Raloxifene and <span style="font-variant: small-caps">n</span>-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa

Raloxifene and <span style="font-variant: small-caps">n</span>-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin disease caused by mutation of the <i>COL7A1</i> gene. RDEB is associated with high levels of TGF-β1, which is likely to be involved in the fibrosis that develops in this disease. Endoglin (CD105) is a type III coreceptor...

Full description

Bibliographic Details
Main Authors: Tania Aguado, Marta García, Adela García, Gemma Ferrer-Mayorga, Lucía Martínez-Santamaría, Marcela del Río, Luisa-María Botella, José-María Sánchez-Puelles
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cells
Subjects:
epidermolysis bullosa
TGF-fibrosis
raloxifene
N-acetylcysteine
endoglin
smad
Online Access:https://www.mdpi.com/2073-4409/9/9/2108

Internet

https://www.mdpi.com/2073-4409/9/9/2108

Similar Items